Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma.


Journal

Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459

Informations de publication

Date de publication:
05 2021
Historique:
received: 07 02 2020
accepted: 13 11 2020
revised: 24 10 2020
pubmed: 4 12 2020
medline: 10 7 2021
entrez: 3 12 2020
Statut: ppublish

Résumé

We present three patients with aggressive non-Hodgkin's B-cell lymphoma (NHL) who received anti-CD19 chimeric antigen receptor T (CAR T) cells therapy after failure of several lines of chemotherapy that developed pseudo-progression. One-week clinical and radiological findings were consistent with tumor progression. Positron emission tomography-computed tomography (PET-CT) at 1 month post CAR T cells administration was consistent with treatment response. The rapid tumor growth and subsequent resolution are suggestive of tumor pseudo-progression mediated secondary to infiltration and immune activation of CAR T cells. Overall, 56 adult patients with NHL were enrolled in a phase 1b/2 in house clinical study with CD19 CAR T cells. Out of them 22/56 patients progressed as per PET-CT the 1 month post CAR T cells. In 14 patients, signs of progression started 7-10 days after CAR T cells infusion. In 11/14 patients, it was true progression, while in 3 it was pseudo-progression. Additional studies are warranted to describe the extent of this phenomenon and evaluate correlation with the CAR T activity and long-term disease control.

Identifiants

pubmed: 33268830
doi: 10.1038/s41409-020-01156-y
pii: 10.1038/s41409-020-01156-y
pmc: PMC8113054
doi:

Substances chimiques

Antigens, CD19 0
Receptors, Chimeric Antigen 0

Types de publication

Clinical Trial, Phase I Clinical Trial, Phase II Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1134-1143

Références

Clin Cancer Res. 2015 Nov 15;21(22):4989-91
pubmed: 26567357
Memo. 2018;11(2):138-143
pubmed: 29983829
Ann Oncol. 2010 Aug;21(8):1712-1717
pubmed: 20147741
Pigment Cell Melanoma Res. 2016 Sep;29(5):572-7
pubmed: 27333363
Blood. 2008 Jun 1;111(11):5291-7
pubmed: 18334676
Int Immunopharmacol. 2018 May;58:125-135
pubmed: 29579717
Ann Oncol. 2017 Aug 01;28(8):1988-1995
pubmed: 28595336
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Mayo Clin Proc. 2019 Jul;94(7):1321-1329
pubmed: 31272574
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
Cytokine Growth Factor Rev. 2001 Dec;12(4):375-91
pubmed: 11544106
Ann Oncol. 2009 Feb;20(2):309-18
pubmed: 18842613
Eur J Haematol. 2016 Apr;96(4):389-96
pubmed: 26115358
Radiographics. 2015 Mar-Apr;35(2):424-37
pubmed: 25763727
Mol Ther. 2017 Oct 4;25(10):2245-2253
pubmed: 28803861
AJR Am J Roentgenol. 2010 Sep;195(3):W221-8
pubmed: 20729419
J Clin Oncol. 2018 May 10;36(14):1428-1439
pubmed: 29584546
Biochem Biophys Res Commun. 1987 Dec 16;149(2):755-61
pubmed: 3322281
Ann Oncol. 2004 Oct;15(10):1481-3
pubmed: 15367407
Mol Ther. 2017 Jan 4;25(1):285-295
pubmed: 28129122
Biol Blood Marrow Transplant. 2019 Dec;25(12):2305-2321
pubmed: 31446199
Blood. 2016 Nov 24;128(21):2489-2496
pubmed: 27574190
J Clin Oncol. 2014 Apr 1;32(10):1020-30
pubmed: 24590637
Am J Hematol. 2018 Dec;93(12):1485-1492
pubmed: 30187944
Clin Cancer Res. 2014 Nov 15;20(22):5697-707
pubmed: 25224278
Cancer Immunol Immunother. 2009 Aug;58(8):1297-306
pubmed: 19139884
J Immunother Cancer. 2016 Dec 20;4:84
pubmed: 28018599
J Clin Oncol. 2015 Feb 20;33(6):540-9
pubmed: 25154820
J Clin Oncol. 2016 May 1;34(13):1510-7
pubmed: 26951310
Cancer Immunol Immunother. 2012 Jan;61(1):41-8
pubmed: 21833591
Biol Blood Marrow Transplant. 2019 Jun;25(6):1092-1098
pubmed: 30769193
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
N Engl J Med. 2017 Dec 28;377(26):2545-2554
pubmed: 29226764
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
N Engl J Med. 2013 Jul 11;369(2):122-33
pubmed: 23724867
J Clin Oncol. 2006 Dec 1;24(34):5343-9
pubmed: 17088571

Auteurs

Ivetta Danylesko (I)

Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel. alexivetta@gmail.com.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. alexivetta@gmail.com.

Roni Shouval (R)

Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Noga Shem-Tov (N)

Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Ronit Yerushalmi (R)

Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Elad Jacoby (E)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.

Michal J Besser (MJ)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel.

Avichai Shimoni (A)

Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Tima Davidson (T)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Nuclear Medicine, Sheba Medical Center, Ramat Gan, Israel.

Katia Beider (K)

Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Dror Mevorach (D)

Department of Medicine, Rheumatology Research Center, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Shalev Fried (S)

Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Arnon Nagler (A)

Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Abraham Avigdor (A)

Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH